Mannatech, Incorporated (NASDAQ:MTEX – Get Free Report) Director Kevin Andrew Robbins bought 7,100 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was purchased at an average price of $4.17 per share, with a total value of $29,607.00. Following the completion of the transaction, the director directly owned 33,333 shares of the company’s stock, valued at approximately $138,998.61. The trade was a 27.07% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mannatech Trading Up 2.6%
Shares of MTEX stock traded up $0.11 on Wednesday, hitting $4.32. The company had a trading volume of 57,830 shares, compared to its average volume of 24,752. The firm has a market cap of $8.34 million, a P/E ratio of -0.64 and a beta of 0.61. The stock’s 50-day moving average is $5.62 and its two-hundred day moving average is $7.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.59 and a current ratio of 1.09. Mannatech, Incorporated has a twelve month low of $3.89 and a twelve month high of $12.45.
Mannatech (NASDAQ:MTEX – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.49 earnings per share for the quarter. The company had revenue of $24.92 million during the quarter. Mannatech had a negative return on equity of 2,383.34% and a negative net margin of 11.97%.
About Mannatech
Mannatech, Inc is a global health and wellness company that develops and markets a range of dietary supplements and personal care products through a direct selling business model. The company’s core focus is on glyconutrients, specialized carbohydrates believed to support cellular communication, which form the basis of many of its flagship offerings. Operating under a network marketing structure, Mannatech empowers independent associates to promote and distribute its products in markets around the world.
The company’s product portfolio includes nutritional supplements aimed at immune support, digestive health, and healthy aging, as well as skincare items designed to promote hydration and skin vitality.
See Also
- Five stocks we like better than Mannatech
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
